Polycomb-mediated loss of miR-31 activates NIK-dependent NF-κB pathway in adult T cell leukemia and other cancers.

Constitutive NF-κB activation has causative roles in adult T cell leukemia (ATL) caused by HTLV-1 and other cancers. Here, we report a pathway involving Polycomb-mediated miRNA silencing and NF-κB activation. We determine the miRNA signatures and reveal miR-31 loss in primary ATL cells. MiR-31 negatively regulates the noncanonical NF-κB pathway by targeting NF-κB inducing kinase (NIK). Loss of miR-31 therefore triggers oncogenic signaling. In ATL cells, miR-31 level is epigenetically regulated, and aberrant upregulation of Polycomb proteins contribute to miR-31 downregulation in an epigenetic fashion, leading to activation of NF-κB and apoptosis resistance. Furthermore, this emerging circuit operates in other cancers and receptor-initiated NF-κB cascade. Our findings provide a perspective involving the epigenetic program, inflammatory responses, and oncogenic signaling.

[1]  P. Ramakrishnan,et al.  Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase. , 2004, Immunity.

[2]  G. Cheng,et al.  Control of canonical NF-κB activation through the NIK–IKK complex pathway , 2008, Proceedings of the National Academy of Sciences.

[3]  Toshiki Watanabe,et al.  The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma. , 2004, Cancer cell.

[4]  O. Hermine,et al.  Deregulation of microRNA involved in hematopoiesis and the immune response in HTLV-I adult T-cell leukemia. , 2009, Blood.

[5]  Huidong Shi,et al.  Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. , 2009, Blood.

[6]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[7]  Rameen Beroukhim,et al.  An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB , 2010, Nature Medicine.

[8]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Ogawa,et al.  Oncogenic mutations of ALK kinase in neuroblastoma , 2008, Nature.

[10]  K. Yamaguchi,et al.  Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. , 2005, Blood.

[11]  T. Mak,et al.  Activation of noncanonical NF-κB requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2, TRAF3 and the kinase NIK , 2008, Nature Immunology.

[12]  E. Harhaj,et al.  Regulation of the NF-κB-inducing Kinase by Tumor Necrosis Factor Receptor-associated Factor 3-induced Degradation* , 2004, Journal of Biological Chemistry.

[13]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[14]  K. Jeang,et al.  Roles for microRNAs, miR-93 and miR-130b, and tumor protein 53-induced nuclear protein 1 tumor suppressor in cell growth dysregulation by human T-cell lymphotrophic virus 1. , 2008, Cancer research.

[15]  D. Wallach,et al.  MAP3K-related kinase involved in NF-KB induction by TNF, CD95 and IL-1 , 1997, Nature.

[16]  D. Cooper,et al.  Retroviral delivery of promoter-targeted shRNA induces long-term silencing of HIV-1 transcription. , 2009, Microbes and infection.

[17]  Robert A. Weinberg,et al.  A Pleiotropically Acting MicroRNA, miR-31, Inhibits Breast Cancer Metastasis , 2009 .

[18]  P. Ramakrishnan,et al.  Receptor-Specific Signaling for Both the Alternative and the Canonical NF-κB Activation Pathways by NF-κB-Inducing Kinase , 2004 .

[19]  Anke Sparmann,et al.  Polycomb silencers control cell fate, development and cancer , 2006, Nature Reviews Cancer.

[20]  S. Varambally,et al.  Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer , 2008, Science.

[21]  J. Inazawa,et al.  Overexpressed NF-kappaB-inducing kinase contributes to the tumorigenesis of adult T-cell leukemia and Hodgkin Reed-Sternberg cells. , 2008, Blood.

[22]  B. Chait,et al.  Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement , 2003, Nature Immunology.

[23]  K. Yamaguchi,et al.  Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. , 2010, Blood.

[24]  Christoph Wülfing,et al.  Polycomb Group Protein Ezh2 Controls Actin Polymerization and Cell Signaling , 2005, Cell.

[25]  Robert E. Kingston,et al.  Mechanisms of Polycomb gene silencing: knowns and unknowns , 2009, Nature Reviews Molecular Cell Biology.

[26]  M. Rosenfeld,et al.  The RNA-binding Protein KSRP Promotes the Biogenesis of a Subset of miRNAs , 2016 .

[27]  G. Kristiansen,et al.  Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma , 2009, International journal of cancer.

[28]  K. Yamaguchi,et al.  Human T lymphotropic virus type-I and adult T-cell leukemia in Japan , 2002, International journal of hematology.

[29]  A. Rabson,et al.  NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? , 2004, Journal of cellular biochemistry.

[30]  Andrea Ventura,et al.  MicroRNAs and Cancer: Short RNAs Go a Long Way , 2009, Cell.

[31]  S. Ghosh,et al.  Shared Principles in NF-κB Signaling , 2008, Cell.

[32]  A. Rabson,et al.  NF‐κB activation in human prostate cancer: Important mediator or epiphenomenon? , 2004 .

[33]  N. Mori,et al.  Tax-independent constitutive IkappaB kinase activation in adult T-cell leukemia cells. , 2004, Neoplasia.

[34]  J. Pollack,et al.  MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. , 2008, Blood.

[35]  G. Lyons,et al.  The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. , 2004, Genes & development.

[36]  B. Aggarwal,et al.  NF-κB and cancer: how intimate is this relationship , 2010, Molecular and Cellular Biochemistry.

[37]  L. Staudt,et al.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. , 2007, Cancer cell.

[38]  A. Richmond,et al.  NF-κB inducing kinase: a key regulator in the immune system and in cancer. , 2010, Cytokine & growth factor reviews.

[39]  A. Hata,et al.  SMAD proteins control DROSHA-mediated microRNA maturation , 2008, Nature.